Lilly and Boehringer's Jardiance shows benefits for those with 'intimately linked' heart failure and kidney disease UnitedHealth Group again the most profitable payer in Q3 Fierce Biotech’s Rotten Tomatoes 2021 He got the first postpartum depression drug to market. Now, ex-Sage CMO takes helm at Ancora to revive a Taisho drug Many expectant mothers unlikely to get vaccinated for COVID-19, survey finds GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog AstraZeneca Samsung Pharm hit with 3-month production suspension from Korean regulators Kaiser Permanente's hospital-at-home push prioritizes savings over high-quality care, nurses union says Alcon scopes out $475M acquisition of glaucoma stent maker Ivantis Takeda launches value-based pricing program for lung cancer med Alunbrig, promises more deals to come Philips augments cardiac AI diagnostic programs with Cardiologs acquisition NHS lands £250M in government funding to update diagnostic services Featured Story | By Kevin Dunleavy New data from Eli Lilly and Boehringer Ingelheim on Jardiance show that it can reduce the risk of death and hospitalization from heart failure while also slowing the decline of kidney function. There are no approved treatments that have been proven to significantly improve outcomes across the full spectrum of heart failure. read more |
| |
|---|
|
|
| Seven Keys to Success in Europe For emerging companies seeking to expand into Europe, there are many complexities and potential pitfalls. This 77-page e-book outlines the 7 keys to success when entering Europe for the first time. Download now. |
Top Stories By Paige Minemyer UnitedHealth Group has topped the industry in profitability for the third straight quarter, according to company earnings reports. read more By Ben Adams The biopharma industry has received acclaim during the COVID-19 pandemic. But while some companies have been working hard on life-saving therapies, others' actions have further stained the industry's already shaky reputation. read more By Kyle LaHucik In its quest to revive a failed Taisho depression drug, Ancora Bio needed a leader with experience getting a therapy to market for the depression field. So, the Joe Jimenez-founded biotech has snagged Sage CMO Stephen Kanes, who secured the first FDA approval for a postpartum depression drug. read more By Anastassia Gliadkovskaya Ovia Health, a family benefits solution, conducts monthly surveys of 4,500 users across each of its various apps on their attitudes toward the COVID-19 vaccine. Most remain hesitant, though most have discussed the benefits with their provider. read more By Nick Paul Taylor GlaxoSmithKline has boosted its challenge for the anemia due to chronic kidney disease market, revealing a clean sweep of hits on key endpoints across two phase 3 clinical trials. But with the FDA rejecting AstraZeneca’s rival drug, doubts remain about GSK’s chances of getting to market. read more By Joseph Keenan Samsung Pharm was hit with a three-month suspension of all manufacturing operations after Korea’s Ministry of Food and Drug Safety found the company was using one production manager to oversee operations at two separate facilities. read more By Dave Muoio National Nurses United argued that Kaiser Permanente's cost-minded hospital-at-home programs limit the role of nurses and, subsequently, reduce the care patients receive. The system responded that the program does not compromise treatment and that hospital nurses "will continue to play a critically important and highly valued role." read more By Andrea Park Three years after Alcon pulled its CyPass Micro-Stent from the market due to safety concerns, the Novartis spinoff has found another glaucoma treatment device to take its place. read more By Angus Liu As the targeted treatment space for ALK-positive non-small cell lung cancer becomes more crowded, Takeda is trying to get ahead of the competition with a drug pricing tool that’s rarely used among U.S. oncology players. read more By Conor Hale Following a multibillion-dollar acquisition late last year to grow its cardiac connected care franchise, Philips is continuing the effort with a new deal to take over Cardiologs, a French startup developing artificial-intelligence-powered diagnostics. read more By Andrea Park The funding has been earmarked specifically for technological improvements to the NHS’ diagnostic services, with a goal of streamlining the entire process of ordering, performing and reviewing tests to detect and begin treating health conditions as early as possible. read more | 